Preventative Treatment Trials (Adjuvant)

Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

14 trials found

Imatinib

Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery (Z9000)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00025246 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country


Imatinib

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor (RTOG-S-0132)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00028002 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country


Imatinib

Imatinib Mesylate (Gleevec; STI571) in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed by Surgery (ACOSOG-Z9001)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00041197 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country


Imatinib

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor (EORTC-62024)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00103168 Conditions: Gastrointestinal Stromal Tumor
Status:
Unknown
Site
City
State
Country


Imatinib

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (SSGXVIII/AIO)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00116935 Conditions: GIST Sarcoma
Status:
Completed
Site
City
State
Country
Helsinki University Central Hospital Helsinki Finland
Lund University Hospital Lund Sweden


Imatinib

Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) (Japan CSTI571BJP07)
Phase: 
4 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00171977 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country
Site name unknown, Tokyo Tokyo Japan


Imatinib

Adjuvant Imatinib in High-Risk GIST With c-Kit Mutation (ROK CSTI571BKR08)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00278876 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country


Imatinib

Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST (MDACC)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00500188 Conditions: GIST
Status:
Completed
Site
City
State
Country
MD Anderson Cancer Center Houston TX USA


Imatinib

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST) (Novartis CSTI571BUS282)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT00867113 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
Moores Cancer Center/UCSD Medical center La Jolla CA USA
Cedars-Sinai Outpatient Cancer Center Los Angeles CA USA
University of Colorado Aurora CO USA
Washington Cancer Institute Washington DC USA
Northeast Georgia Cancer Center (ACORN) Athens GA USA
NE Georgia Health Systems Gainesville GA USA
Kootenai Cancer Center Coeur d'Alene ID USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
North Shore University Health Systems Evanston IL USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Southern Nevada Cancer Research center Las Vegas NV USA
Dartmouth-Hitchcock Medical Center Lebanon NH USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Montefiore North Bronx NY USA
Queens Cancer Center of Queens Regional Hospital Jamaica NY USA
Duke University Durham NC USA
Wake Forrest Winston-Salem NC USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
Fox Chase Cancer Center Philadelphia PA USA
Pennsylvania State University Hershey PA USA
Roger Williams Medical Center Providence RI USA
Kingsport Hematolog Oncology Kingsport TN USA
MD Anderson Cancer Center Houston TX USA
South Texas Oncology Hematology San Antonio TX USA
Virginia Oncology Associates Norfolk VA USA
Emory University Hospital Midtown (EUHM) Atlanta GA USA
Wayne State University Wertz Clinical Cancer Center Detroit MI USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA


Imatinib

Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST) (IMAGE) (Novartis CSTI571BIC08)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT01172548 Conditions: Gastrointestinal Stromal Tumor
Status:
Completed
Site
City
State
Country
Site name unknown - Algiers Algiers Algeria
Site name unknown - Cairo Cairo Egypt
Site name unknown Delhi New Delhi Delhi India
Site name unknown Mumbai Mumbai Mumbai India
Site name unknown - Pune Pune India
Site name unknown - Ahmedabad Ahmedabad India
Site name unknown - Amman Amman Jordan
Site name unknown - Beirut Beirut Lebanon
Site name unknown - Saida Saida Lebanon
Site name unknown - Moscow Moscow Russia
Site name unknown - Irkutsk Irkutsk Russia
Site name unknown - Kazan Kazan Russia
Site name unknown - Kursk Kursk Russia
Site name unknown - Omsk Omsk Russia
Site name unknown - St. Petersburg St. Petersburg Russia
Site name unknown - Yekaterinburg Yekaterinburg Russia
Site name unknown - Riyadh Riyadh Saudi Arabia
Site name unknown - Pretoria Pretoria South Africa
Site name unknown - Johannesburg Johannesburg South Africa
Site name unknown - Kaohsiung Kaohsiung County Taiwan
Site name unknown - Taichung Taichung Taiwan
Site name unknown - Tainan Tainan City Taiwan
Site name unknown - Taipei Taipei Taiwan
Site name unknown - Taoyuan Taoyuan County Taiwan
Site name unknown - Songkla Songkla Thailand
Site name unknown Bangkok Bankok Thailand
Site name unknown - Tunis Tunis Tunisia
Site name unknown - Ankara Ankara Turkey
Site name unknown - Istanbul Istanbul Turkey
Site name unknown - Izmir Izmir Turkey
Site name unknown - Cairo Cairo Egypt


Imatinib

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT02260505 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Centre Léon Bérard Lyon Rhone France
Institut Paoli-Calmette Marseille Bouches du Rhone France
La Timone University Hospital, Medical Oncology Unit Marseille Bouches du Rhone France
Hôpital Jean Minjoz Besancon Doubs France
Institut Bergonie Bordeaux Gironde France
Hopital Europeen Georges Pompidou Paris Ile de France France
St. Herblain Nantes Loire Atlantique France
Centre Oscar Lambret - Lille Lille Nord France
Institut de Cancérologie Neuwirth Saint Priest en Jarez Loire France
Hopital Robert Debre Reims Marne France
Institut Gustave Roussy Villejuif Val de Narne France
Hôpital St Antoine Paris France
Centre Hospitalier Universitaire Toulouse Purpan Toulouse Haut-Garonne France
Centre Régional de Lutte contre le Cancer de Montpellier Montpellier Herault France
Institut de Cancérologie de Lorraine Vandoeuvre-les-Nancy Meurthe et Moselle France
CHRU Strasbourg - Hôpital Hautepierre Strasbourg France


Imatinib

Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy (ABILITY)
Phase: 
1 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT02185937 Conditions: Gastrointestinal Stromal Tumor
Status:
Terminated
Site
City
State
Country
University Medical Center Nijmegen st Raboud Nijmegen Gelderland Netherlands


Imatinib

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
Phase: 
3 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT02413736 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Helsinki University Central Hospital Helsinki Finland


Imatinib

The Stop-GIST Trial: Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor
NCT#:
NCT02924714 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Oslo University Hospital Oslo Norway


14 trials found